Rethinking Fuchs Dystrophy in the Era of Successful Descemet Stripping

In this interview from AAO 2018, Dr. Kathryn Colby reviews her Whitney G. Sampson Lecture on the use of Descemet stripping for treating Fuchs endothelial corneal dystrophy (FECD). This disease is the most common indication for corneal transplantation, and affects up to 4% of ophthalmology patients in the United States. The revolution in the surgical treatment of FECD over the past 15 years, including the recent demonstration that Descemet stripping only can be used as a treatment in certain FECD patients, has led to renewed interest in this corneal condition. Dr. Colby discusses her latest work that begins to tease apart the cause(s) of FECD, as well as reviews the future for nongraft therapies.

Relevant Financial Disclosures: None